AlphAIalphai — Financial news for AI agents
financialcontent.comAUG 52 min read$XRAY

Earnings To Watch: Dentsply Sirona (XRAY) Reports Q2 Results Tomorrow

Dentsply Sirona (XRAY) will report Q2 results Thursday after market hours. The company previously reported $880M revenue, flat year over year, and EPS that beat full-year guidance estimates. For the upcoming quarter, analysts expect revenue to fall 4.6% y/y. The article cites an average analyst price target of $13.44 versus $14.25 current.

Original reporting
financialcontent.com
Published Aug 5, 2026, 3:45 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 5, 2026, 4:45 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Earnings To Watch: Dentsply Sirona (XRAY) Reports Q2 Results Tomorrow — source image
Source · financialcontent.com
Decision brief

The 30-second read

$XRAYNeutralMed
01

Why it matters

Traders can use the consensus revenue decline expectation and peer results as a short-term volatility map, but there is no new company-specific financial disclosure in the text itself.

02

Market read

This is a pre-earnings positioning brief for XRAY, centered on consensus revenue expectations and peer read-throughs.

03

What to watch

The article does not discuss margins, guidance details, or any specific operational drivers that typically determine post-earnings repricing.

Relevance 4/10Novelty 4/10Timing: pre-market positioning ahead of Thursday after-hours earnings

Background

The article frames Dentsply Sirona’s upcoming Q2 earnings, referencing last quarter’s revenue beat and the market’s expectation for another YoY revenue decline.

Company-level read

Ticker impact

$XRAYNeutralMedium confidence
Context

Dentsply Sirona is scheduled to report Q2 results after the close this Thursday, with the article citing consensus revenue decline and recent estimate reconfirmations.

Expected impact

Likely volatility around the print versus the expected 4.6% YoY revenue decline, with direction dependent on whether results beat or miss consensus.

Evidence & confidence

The text is a pre-earnings setup using consensus and peer read-throughs, not a fresh disclosure like guidance, a contract, or a regulatory action.

Market effects

Sector

Healthcare equipment and supplies names are being used for read-through (Henry Schein, Align Technology), implying traders may trade the group on relative beats/misses.

Regional

Primarily US-focused as the catalyst is a US-listed earnings release.

Global

Limited, since the article does not cite global regulatory, supply-chain, or macro shocks.

Counterpoint

What could challenge this read

If the company’s prior-quarter pattern of beating revenue expectations repeats, the stock could outperform despite the consensus YoY decline.

Key entities

  • company
    Dentsply Sirona

    NASDAQ-listed dental products company reporting Q2 results after market hours this Thursday.

  • company
    Henry Schein

    Peer cited as having reported Q2 revenue growth and a beat versus expectations.

  • company
    Align Technology

    Peer cited as having reported revenues in line with consensus and trading down after results.

Read at source← All news

Related articles

SEP 3
$XRAYMedAI 8/10

Dentsply Sirona (XRAY) Swings Back To Profit While Sales Keep Sliding

Dentsply Sirona (XRAY) reported Q2 2026 net sales of $898M, down 4.1% YoY, but swung to a $37M profit from a $45M loss. Adjusted EPS was $0.52, down 1.6% YoY. Margins improved, and cash flow tripled. The company repurchased 1.3M shares and expanded a partnership. Sales declined in most segments, with Orthodontic and Implant Solutions down 13.2%. Full-year guidance was reiterated. Hedge fund ownership fell, and short interest is high at 11.01% of float. Shares trade at a forward P/E of 6.97.

insidermonkey.com3 min
AUG 26
$XRAYMed

Dentsply Sirona Reports Strong PrimeTaper EV Results

Dentsply Sirona (XRAY) reported 98.5% implant survival and 95.6% success rate for its PrimeTaper EV system in a one-year study. The study, conducted across five international centers, showed progressive stability and minimal bone changes. The company highlights its commitment to evidence-based dentistry and extensive research.

dentistrytoday.com2 min
AUG 14
$XRAYMedAI 8/10

Dentsply Sirona (XRAY) Q2 2026 Earnings Call Transcript

Dentsply Sirona (XRAY) reported Q2 2026 revenue of $898 million, down 4.1% reported (6.3% constant currency). Adjusted EPS was $0.52. Tariff refunds were $44 million, aiding operating cash flow of $99 million. Full-year revenue guidance was maintained at $3.5 to $3.6 billion and adjusted EPS at $1.40 to $1.50.

fool.com6 min
AUG 9
$XRAYMed

DENTSPLY SIRONA Q2 Earnings Call Highlights

Dentsply Sirona (NASDAQ:XRAY) reported Q2 segment sales declines amid uneven regional demand and higher operating expenses, including an $8 million FX headwind. Connected Technology Solutions sales were $239M, down 1.5%. Orthodontic and Implant Solutions revenue fell 13.2% to $197M. The company maintained 2026 net sales guidance of $3.5B to $3.6B and adjusted EPS of $1.40 to $1.50.

yahoo.com6 min
AUG 7
$XRAYMedAI 8/10

Why Dentsply Sirona (XRAY) Stock Is Trading Lower Today

Dentsply Sirona (XRAY) shares fell about 7% after the company reported Q2 2026 results. Revenue declined 4.1% to $898 million and topped expectations, while adjusted EPS of $0.52 beat estimates. The stock dropped on a weaker full-year revenue forecast of $3.55 billion at the midpoint, about 1% below consensus.

financialcontent.com3 min
AUG 7
$XRAYMedAI 8/10

XRAY Stock Falls Despite Q2 Earnings Beat, Wellspect Drives Sales

Dentsply Sirona (XRAY) reported Q2 2026 adjusted EPS of 52 cents, down 1.6% YoY but above the Zacks Consensus estimate of 36 cents. Revenue fell 4.1% to $898 million. Wellspect Healthcare growth helped offset declines in other dental segments. The company kept 2026 net sales guidance at $3.5B-$3.6B and adjusted EPS at $1.40-$1.50.

tradingview.com6 min